Background: To better understand the extent of the magnitude of tuberculosis (TB) and Human Immunodeficiency Virus (HIV) co-infection in Ghana, a baseline study was conducted to establish the national prevalence of the dual infection. The study aimed to determine the most prevalent HIV serotype (HIV-1 or HIV-2) in TB patients (new and old cases); genotype mycobacterial species causing TB/HIV co-infection and determine their drug susceptibility patterns. Methods: Sputum and dried blood samples were collected from 503 TB patients from 67 health facilities nationwide between December 2007 and November 2008. All samples were processed for mycobacterial and HIV testing using conventional and molecular methods. Results: A total of 517 paired sputum samples were received from 517 patients. A total 503 patients [335 (66.6%) males; 168 (33.4%) females] had at least one culture positive sample. Majority (93.0%) of the patients were new cases while 7.0% were old cases. All 503 TB isolates were Mycobacterium tuberculosis complex. Of 503 blood samples, 74 were positive for HIV (14.7%), comprising 71 (14.1%) and 3 (0.6%) for HIV-1 and HIV-1 & 2 respectively; none was positive for HIV-2 alone. The seroprevalence of HIV in newly diagnosed TB patients and those already on treatment, was 69/468 (14.7%) and 5/35 (14.3%) respectively (p > 0.05). Differentiation of isolates from TB/HIV co-infected patients showed that 70/74 (94.6%) were Mycobacterium tuberculosis while 4/74 (5.4%) were Mycobacterium africanum. Monoresistance to isoniazid and rifampicin were 4/74 (5.4%) and 1/74 (1.4%) respectively; resistance to both drugs (multi-drug resistant-MDR) was not observed. Sixty nine (93.2%) isolates were susceptible to both drugs. Conclusion: The prevalence of HIV infection in TB patients How to cite this paper:
Introduction
The syndemic relationship between tuberculosis (TB) and human immunodeficiency virus (HIV) infection has contributed to high morbidity and mortality worldwide [1] . The World Health Organization (WHO) Africa region is the hardest hit where about 74% of the estimated 1.2 million TB patients co-infected with HIV occurred in 2014 [2] . For many years, efforts to tackle TB and HIV have been largely independent of each other, despite their overlapping epidemiology. The risk of progression from latent to active TB is increased by infection with HIV [3] . Likewise, TB is the most important opportunistic disease that increases progression to acquired immune deficiency syndrome (AIDS) and the number one killer in HIV-positive individuals [4] [5] . Thus effective TB control can contribute to better HIV/AIDS control by reducing the TB burden in people with HIV as well as providing an entry point to HIV prevention and care for people with TB [6] . The HIV prevalence in the general population in Ghana was 1.47% in 2014 which is an indication of a downward trend over a fifteen-year period from 2.3% in 2000 [7] . Studies in Africa and Asia have reported high HIV prevalence in TB patients than are observed in the general population [8] . Routine programme data from TB/HIV sites showed that in 2005, 40 percent of TB patients who were tested for HIV were HIV-positive and in 2006 these went down to 33 percent [9] [10] . Ghana is a high burden TB/HIV country [11] , however very few studies have reported on the prevalence of TB/HIV co-infection in Ghana [12] [13] [14] . These previous studies were single hospital-based in the two big cities in Ghana-Accra and Kumasi. There was the need to conduct a nationwide study to establish the national prevalence of this dual infection. This study was therefore conducted to determine the prevalence of HIV in TB patients in Ghana.
Materials and Methods

Study Design
The study was cross-sectional in accordance with WHO Guidelines for HIV surveillance among TB patients [15] . and grouped into northern and southern sectors ( Table 1) . Selection of study participants was done using the consecutive sampling method to minimize bias.
Study Population and Sampling Strategy
Hence, every patient who met the eligibility criteria was selected and after obtaining his/her informed consent was interviewed using a structured questionnaire.
Sample Size Calculation
The minimum sample size was calculated using the formula: N = PQ/(E/Z) 2 [15] where N = the minimum sample size required; P = the maximum expected prevalence rate; Q = 100 -P; E = the margin of sampling error tolerated; Z = the centile of the standard normal
If the confidence level is chosen at 95% then Z = 1.96 With the expected HIV prevalence rate among TB patients (P) at 30% Q will be 100 -30 = 70; and margin of error at 5%, the minimum sample size was:
( ) 
Sample Collection and Transport
For each eligible patient, an equal volume of 1% Cetylpyridinium Chloride (CPC) was added to two sputum samples for homogenization and decontamination on transit and to maintain the viability of the bacilli if present. Blood was collected onto blood spot collection card to prepare dried blood spot according to the study specific protocol [16] . All the samples were stored at 4˚C and transported within one week to Noguchi Memorial Institute for Medical Research (NMIMR) TB Laboratory for analysis.
Mycobacterial Identification and Drug Susceptibility Testing (DST)
Preliminary identification was made by the detection of acid fast bacilli (AFBs) in sputum samples by smear examination, using the Ziehl-Neelsen (ZN) staining technique. Subsequently, sputum samples were processed according to WHO guidelines [17] . Briefly, decontaminated sputum samples were centrifuged at were reconstituted with sterile phosphate buffer saline (PBS) and about 2 -3 drops inoculated onto two slopes of Lowenstein-Jensen (LJ) media; one containing glycerol, the other containing 0.5% sodium pyruvate. The inoculated tubes were incubated at 37˚C and monitored weekly for a maximum of 8 weeks for growth and subsequent isolation of mycobacterial species. Final identification of the species were based on acid fastness, colony morphology and ability to grow on LJ media containing 500 mg/ml p-nitrobenzoic acid (PNB) [18] . Line probe assay (LPA) was done to differentiate and determine isoniazid and rifampicin susceptibility profile of mycobacterial isolates from TB/HIV patients using Geno Type MTBC and Geno Type MTBDR plus (Hain Lifescience, Nehren
Germany) respectively according to manufacturer's instructions [19] .
HIV Testing
All patients were offered pre and post counselling for HIV test according to national guidelines [6] . Initial screening for HIV was done by eluting blood from filter paper and testing with First Response anti-HIV 1 & 2 (Premier Medical Corporation, India). This test simultaneously detects and indicates specific antibodies against HIV-1 and HIV-2. Next, all HIV reactive samples were subjected to a line immunoblot assay, the Inno-Lia Score HIV-I & II (Innogenetics, Belgium) to confirm the presence of HIV-1 and HIV-2 antibodies. Quality control of the HIV test was performed by random testing of 10% of HIV non-reactives from the rapid assay on the line immunoblot assay.
Data Management and Analysis
Raw data on-site were double entered into a data entry file- 
Ethical Considerations
The study was approved by the Scientific and Technical Committee and the Institutional Review Board of Noguchi Memorial Institute for Medical Research, Federal Wide Assurance 00001824 (NMIMR-IRB CPN 022/02-03). All patients involved in the study gave their informed consent prior to participation.
Results
Sixty seven health facilities from the northern and southern sectors of Ghana were involved in the study ( None of the samples were positive for HIV-2 infection alone (Table 3 ). All the 503 isolates were Mycobacterium tuberculosis complex (MTBC) based on phenotypic identification. The LPA run for all 74 isolates from TB/HIV co-infected patients showed that 70 (94.6%) were Mycobacterium tuberculosis while the remaining 4 (6%) were Mycobacterium africanum (Table 4 ). Monoresistance to isoniazid and rifampicin were 4 (5.4%) and 1 (1%) respectively. However, resistance to both drugs (multi-drug resistant-MDR) was not observed. Sixty nine (93%) isolates were susceptible to both drugs ( Figure 1 ). Table 4 . Differentiation of MTBC isolates (N = 74) from TB/HIV co-infected participants using GenoType MTBC Assay. 
Discussion
TB/HIV co-infection is of great public health concern worldwide. This study sought to provide baseline data to inform health policies and actions to address this deadly disease duo in Ghana. Testing for HIV antibodies in TB patients as used in this study seemed an appropriate strategy to determine the burden of TB/HIV. While screening HIV-positive individuals for TB infection may be another option, HIV patients already burdened with stigmatisation may be unwilling to undertake a TB test as well. This assertion corroborates a report [15] showing that TB patients are more likely to accept HIV testing than HIV patients testing for TB. HIV prevalence in TB patients can be used as an indicator of the degree of spread of HIV in the general population. This information is also important for the provision of comprehensive HIV/AIDS care and support. HIV infection rates of up to 48% have been reported among newly diagnosed TB cases in Ghana [20] , but the burden of TB among HIV-infected individuals in Ghana is barely acknowledged. Consistent with the global trend, more males (66.6%) than females (33.4%) were diagnosed with TB in this study [1] . The reasons for gender disparity with regards to TB infection is not well understood though it is believed that some cultural and biological factors may play a role [21] . Majority 70/74 (94.6%) of the TB/HIV co-infected patients were infected with M. tuberculosis which is very similar to what other studies have reported in Ghana [22] [23]. On the contrary, the number of M. africanum (5.4%) isolates was relatively low. Almost 93% of isolates obtained from TB patients were susceptible to both isoniazid and rifampicin. This result may be due to the fact that majority of the patients were new cases and as such had not taken any anti-TB drug before. The overall TB/HIV co-infection prevalence was 14.7% which was consistent with the 14.8% reported earlier in Ghana [9] . However, it was relatively lower than previous rates of 23.2%, 16.8 % and 46.2% respectively reported in Ghana [12] [13] [14] as well as the average rate for Africa (32%) [24] . These previous studies from Ghana were conducted in a very limited number of sites and the study population may not exactly reflect the general population. In Ghana infection with HIV-1 is most common, accounting for over 90% with very few cases of mixed infection of both HIV-1 and HIV-2 reported [25] . Hence it was not surprising to find similar results in this present study. There is an indication that there has been a steady change in the prevalence of TB/HIV co-infection over the last decade. This change in co-infection prevalence might be the result of improvements in public awareness, better treatment regimens and a general decline in HIV prevalence in Ghana [7] . Conversely, TB prevalence in Ghana is reported to be about three times higher than the estimates from WHO prior to the conduct of a TB prevalence survey in 2013 [2] . This suggests that many people are at an increased risk of HIV infection which necessitates a continuous collaborative plan for TB and HIV control activities to ensure comprehensive care for TB/HIV patients.
Some possible limitations in this study were that while TB patients will benefit from this study by knowing their HIV status and thus access treatment and care Journal of Tuberculosis Research for both diseases, the same cannot be said for HIV patients who may be harbouring TB since the study focused on TB infected persons and not HIV infected persons. That notwithstanding, the results have been useful in strengthening the implementation of the joint TB/HIV strategy in Ghana. It has also been a vital biological marker of the HIV/AIDS epidemic in Ghana and indicating the impact on TB infection. Funds for the molecular testing part of the study became available in 2017 hence the delay in the publication of the findings.
Conclusion
The prevalence of TB/HIV co-infection was 14.7%, and co-infection was more common in the sexually active age group of 25 -34 years. Majority of these TB/HIV co-infected patients were infected with M. tuberculosis which were susceptible to both isoniazid and rifampicin. HIV-1 was the most common HIV strain infecting these patients. Further research is needed to monitor the trend and level of interaction between TB and HIV in Ghana.
